{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:02:13Z","timestamp":1780578133046,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,9]]},"DOI":"10.7759\/cureus.43230","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T20:42:25Z","timestamp":1691613745000},"source":"Crossref","is-referenced-by-count":3,"title":["Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab"],"prefix":"10.7759","author":[{"given":"Eric","family":"Olsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami K","family":"Saikaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia A","family":"Missall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Motaparthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune checkpoint inhibitors: basics and challenges","volume":"26","author":"Li B","year":"2019","unstructured":"Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019, 26:3009-25. 10.2174\/0929867324666170804143706","journal-title":"Curr Med Chem"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy","volume":"234","author":"Dermani FK","year":"2019","unstructured":"Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol. 2019, 234:1313-25. 10.1002\/jcp.27172","journal-title":"J Cell Physiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez AT","year":"2018","unstructured":"Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist. 2018, 23:1119-26. 10.1634\/theoncologist.2018-0128","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang K","year":"2022","unstructured":"Tang K, Seo J, Tiu BC, et al.. Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy. JAMA Dermatol. 2022, 158:189-93. 10.1001\/jamadermatol.2021.5476","journal-title":"JAMA Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian MS","year":"2022","unstructured":"Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review. JAMA Dermatol. 2022, 158:933-41. 10.1001\/jamadermatol.2022.1624","journal-title":"JAMA Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.12788\/cutis.0011","article-title":"Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer","volume":"105","author":"Schwartzman G","year":"2020","unstructured":"Schwartzman G, Simpson MM, Jones R, Schiavone K, Coffman M, Meyerle J. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer. Cutis. 2020, 105:E9-12. 10.12788\/cutis.0011","journal-title":"Cutis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01506","article-title":"New insights into the pathogenesis of bullous pemphigoid: 2019 update","volume":"10","author":"Genovese G","year":"2019","unstructured":"Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol. 2019, 10:1506. 10.3389\/fimmu.2019.01506","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos PG","year":"2014","unstructured":"Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol. 2014, 28:1133-40. 10.1111\/jdv.12366","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.001","article-title":"A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes","volume":"87","author":"Bur D","year":"2022","unstructured":"Bur D, Patel AB, Nelson K, Huen A, Pacha O, Phillips R, Heberton M. A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes. J Am Acad Dermatol. 2022, 87:1394-5. 10.1016\/j.jaad.2022.08.001","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.928390","article-title":"The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy","volume":"12","author":"Bruera S","year":"2022","unstructured":"Bruera S, Suarez-Almazor ME. The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Front Oncol. 2022, 12:928390. 10.3389\/fonc.2022.928390","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler AN","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, et al.. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020, 83:1255-68. 10.1016\/j.jaad.2020.03.132","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17999","article-title":"Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study","volume":"36","author":"Velin M","year":"2022","unstructured":"Velin M, Dugourd PM, Sanchez A, Bahadoran P, Montaudi\u00e9 H, Passeron T. Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study. J Eur Acad Dermatol Venereol. 2022, 36:e539-42. 10.1111\/jdv.17999","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000776","article-title":"Systemic treatment of cutaneous adverse events after immune checkpoint inhibitor therapy: a review","volume":"34","author":"Brown AM","year":"2023","unstructured":"Brown AM, Masterson W, Lo J, Patel AB. Systemic treatment of cutaneous adverse events after immune checkpoint inhibitor therapy: a review. Dermatitis. 2023, 34:201-8. 10.1097\/DER.0000000000000776","journal-title":"Dermatitis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby L","year":"2017","unstructured":"Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol. 2017, 153:603-5. 10.1001\/jamadermatol.2017.0091","journal-title":"JAMA Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.05.005","article-title":"T follicular regulatory cells in the regulation of B cell responses","volume":"36","author":"Sage PT","year":"2015","unstructured":"Sage PT, Sharpe AH. T follicular regulatory cells in the regulation of B cell responses. Trends Immunol. 2015, 36:410-8. 10.1016\/j.it.2015.05.005","journal-title":"Trends Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat R","year":"2020","unstructured":"Abdat R, Waldman RA, de Bedout V, et al.. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020, 83:46-52. 10.1016\/j.jaad.2020.01.089","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report","volume":"35","author":"Pop SR","year":"2022","unstructured":"Pop SR, Strock D, Smith RJ. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report. Dermatol Ther. 2022, 35:e15623. 10.1111\/dth.15623","journal-title":"Dermatol Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5070\/D328257396","article-title":"A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab","volume":"28","author":"Bruni M","year":"2022","unstructured":"Bruni M, Moar A, Schena D, Girolomoni G. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab. Dermatol Online J. 2022, 28:10.5070\/D328257396","journal-title":"Dermatol Online J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/12034754221089267","article-title":"Omalizumab for the treatment of bullous pemphigoid: a systematic review of efficacy and safety","volume":"26","author":"D'Aguanno K","year":"2022","unstructured":"D'Aguanno K, Gabrielli S, Ouchene L, et al.. Omalizumab for the treatment of bullous pemphigoid: a systematic review of efficacy and safety. J Cutan Med Surg. 2022, 26:404-13. 10.1177\/12034754221089267","journal-title":"J Cutan Med Surg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13960","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a case series of 13 patients","volume":"64","author":"Yun JS","year":"2023","unstructured":"Yun JS, Chan OB, Goh M, McCormack CJ. Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a case series of 13 patients. Australas J Dermatol. 2023, 64:131-7. 10.1111\/ajd.13960","journal-title":"Australas J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/158669-delayed-onset-of-bullous-pemphigoid-secondary-to-nivolumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:52Z","timestamp":1707508912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/158669-delayed-onset-of-bullous-pemphigoid-secondary-to-nivolumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.43230","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,9]]}}}